TATolu Afolabi

Tolu Afolabi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tolu Afolabi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic Associations and Functional Pathways in Parkinson's Disease: A Meta-Analytic Insight into LRRK2 Mutation Impact

    by John A.Olanrewaju, Ambrose George Oche, Leviticus Arietarhire, Tolu Afolabi, Ezekiel Olugbogbi, Enya Joseph, Oladimeji Somerekun, Joel Irewoluwa, Alessi Dario, Rotimi Fasimoye, et al.

    Background: Parkinson's Disease (PD) is a complex neurodegenerative disorder with elusive pathophysiological mechanisms. Recent studies have highlighted the role of genetic variations and metabolic changes in PD progression. Aim: This study aims to investigate the genetic disparities in PD, particularly focusing on LRRK2 mutations, and to analyze the associated metabolic pathway alterations. Methodology: The study utilized R programming with MetaIntegrator for meta-analysis and ggplot2 for visualization. Datasets underwent preprocessing, and the MetaIntegrator package computed meta scores, effects, and ROC analysis. Differential gene expression and functional enrichment analyses provided insights into genetic associations and pathways in Parkinson's disease and LRRK2 mutations. Results: Significant meta-score differences were observed in PD patients, especially in datasets GSE133347, GSE36321, and GSE100054, underscoring the impact of LRRK2 mutations. Genes like SKAP2 and IFNGR2 were significantly upregulated, implicating their role in neuroinflammation. Moreover, a shift in metabolic pathways, particularly carbohydrate kinase activity, was noted, indicating altered energy metabolism in PD cells. Conclusion: The study reinforces the genetic heterogeneity of PD and highlights the potential therapeutic importance of targeting neuroinflammatory pathways and metabolic dysfunctions. These findings suggest new avenues for diagnostic and therapeutic strategies in PD management.

  • Open Access

    Spondias mombin flavonoids showed super-binder ability with Downstream Molecular Targets of Parkinson’s Disease: Folkloric-therapy assessment as a Scaffold for Structural Studies in Neurodegenerative disease

    by John A. Olanrewaju, Leviticus O. Arietarhire, Oladimeji E. Soremekun, Ezekiel A. Olugbogi, Toluwanimi O. Afolabi, Babatunji E. Oyinloye, Olaposi I. Omotuyi, Steven Russell

    Spondias mombin (S. mombin), a prominent botanical resource, has garnered recognition within folkloric therapy. Parkinson's disease (PD), characterized by dopaminergic neuron attrition in the substantia nigra, manifests as motor anomalies like tremors, rigidity, and bradykinesia. This study capitalizes on S. mombin's reservoir of 100 characterized phytocompounds and employs computational methodologies to interrogate their potential 35 PD-associated target proteins. Employing a multifaceted approach, we engaged in molecular docking, ADMET predictions, Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) evaluations, Density Functional Theory (DFT), and Molecular Dynamic Simulations (MDS). This comprehensive framework facilitated insightful structural assessments and predictive analyses. Impressively, flavonoids hailing from S. mombin, including quercetin, catechin, ellagic acid, and epicatechin, showcased optimal binding affinities for PD-relevant target proteins. Moreover, these identified ligands exhibited minimal signs of mutagenicity, tumorigenicity, or irritancy, except for quercetin, which displayed elevated tumorigenic potential. Notably, quercetin and dopamine exhibited varying band gap energies, with quercetin the lowest (3.63 eV) and dopamine the highest (5.76 eV) values. MDS result suggests a synergistic outcome based on the RMSD and RMSF graphs for quercetin highlighting it as the best of all including the co-ligand. In a collective sense, our findings present S. mombin as promising reservoirs of active pharmaceutical ingredients, warranting further exploration for novel PD therapeutic avenues. Consequently, this study underscores the enhanced efficacy of phyto-ligands sourced from S. mombin, advocating their optimization as potential drug candidates.


  • Vernonia amygdalina Alleviates Neurodegenerative Effects of High Fat Diet and Streptozotocin-Induced Type 2 Diabetes Mellitus in the Hippocampi of Adult Male Wistar Rats

    by Olanrewaju John Afees, Ekundayo Ifeoluwa Olufunmilola, Adeniji Kehinde Oluwaseyi, Enya Joseph Igbo, Leviticus Arietarhire, Oladimeji Soremekun, Olubunmi Ogunbiyi, Richard Bamidele, Adelodun Stephen Taiye, Olatunji Sunday Yinka, et al.

    Cognitive impairment and neurodegeneration are a few hallmarks of brain insulin resistance, a core feature of Type 2 diabetes mellitus (T2DM). Using a Wistar rat model of a high-fat diet and streptozotocin-induced T2DM, we aimed to determine the potential of Vernonia amygdalina (VA) as a possible treatment for the accompanied neurodegenerative effects of this condition on hippocampal structure and function. T2DM adult rats were prepared by a combination of a high-fat diet and intraperitoneal injection of 35 mg/kg streptozocin. The elevated plus and Barnes maze tests were used to evaluate anxiety, learning, and memory functions, followed by H&E and cresyl violet staining, immunohistochemical staining for hippocampal amyloid beta, synaptophysin, and glial fibrillary acid protein (GFAP), and RNA analysis of P53, P21, glutathione (GSH) and glutathione peroxidase (GPX-1) genes expression levels. T2DM model animals had significantly reduced open arm entries and duration and higher escape latencies, depicting increased anxiety and decreased spatial memory and learning abilities(P<0.05). Expression changes were evident for P53, GSH, P21, and GPX-1 genes, which included an increased expression of P53 and P21 in the hippocampus of T2DM model animals and a slight reduction of these genes in VA groups, and an increased expression of GSH in T2DM and VA groups. Also, photomicrographs revealed a fragmented pyramidal cell layer with visible pyknotic cells and a gross reduction in cytoplasmic Nissl proteins across the Cornus Ammonis and dentate gyrus regions of the hippocampi. Similarly, increased expression of amyloid-beta, synaptophysin, and GFAP was seen in these regions. However, V. amygdalina was able to enhance the learning and memory abilities of T2DM rats, replenish hippocampal pyramidal neurons, and help improve hippocampal synapses, while improving the brain’s antioxidant defense system. These findings may provide helpful insights into the treatment of T2DM-induced brain insulin resistance.